Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 EZH2, an epigenetic driver of prostate cancer.

Literature DB >> 23636686

EZH2, an epigenetic driver of prostate cancer.

Abstract

The histone methyltransferase EZH2 has been in the limelight of the field of cancer epigenetics for a decade now since it was first discovered to exhibit an elevated expression in metastatic prostate cancer. It persists to attract much scientific attention due to its important role in the process of cancer development and its potential of being an effective therapeutic target. Thus here we review the dysregulation of EZH2 in prostate cancer, its function, upstream regulators, downstream effectors, and current status of EZH2-targeting approaches. This review therefore provides a comprehensive overview of EZH2 in the context of prostate cancer.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2013 PMID： 23636686 PMCID： PMC4131440 DOI： 10.1007/s13238-013-2093-2

Source DB: PubMed Journal: Protein Cell ISSN： 1674-800X Impact factor: 14.870

108 in total

Review 1. Mechanisms of prostate cancer initiation and progression.

Authors: Beatrice S Knudsen; Valera Vasioukhin
Journal: Adv Cancer Res Date: 2010 Impact factor: 6.242

2. Loading 3-deazaneplanocin A into pegylated unilamellar liposomes by forming transient phenylboronic acid-drug complex and its pharmacokinetic features in Sprague-Dawley rats.

Authors: Feng Sun; Jian Li; Qiang Yu; Eli Chan
Journal: Eur J Pharm Biopharm Date: 2011-10-28 Impact factor: 5.571

3. The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation.

Authors: Giuseppina Caretti; Monica Di Padova; Bruce Micales; Gary E Lyons; Vittorio Sartorelli
Journal: Genes Dev Date: 2004-11-01 Impact factor: 11.361

4. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.

Authors: Jindan Yu; Jianjun Yu; Ram-Shankar Mani; Qi Cao; Chad J Brenner; Xuhong Cao; Xiaoju Wang; Longtao Wu; James Li; Ming Hu; Yusong Gong; Hong Cheng; Bharathi Laxman; Adaikkalam Vellaichamy; Sunita Shankar; Yong Li; Saravana M Dhanasekaran; Roger Morey; Terrence Barrette; Robert J Lonigro; Scott A Tomlins; Sooryanarayana Varambally; Zhaohui S Qin; Arul M Chinnaiyan
Journal: Cancer Cell Date: 2010-05-18 Impact factor: 31.743

5. 16-hydroxycleroda-3,13-dien-15,16-olide regulates the expression of histone-modifying enzymes PRC2 complex and induces apoptosis in CML K562 cells.

Authors: Yi-Hsiung Lin; Chien-Chih Lee; Fang-Rong Chang; Wen-Hsin Chang; Yang-Chang Wu; Jan-Gowth Chang
Journal: Life Sci Date: 2011-09-29 Impact factor: 5.037

6. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.

Authors: Serdar Arisan; Elif Damla Buyuktuncer; Narcin Palavan-Unsal; Turhan Caşkurlu; Omer Onur Cakir; Erbil Ergenekon
Journal: Urol Int Date: 2005 Impact factor: 2.089

7. Polycomb complexes act redundantly to repress genomic repeats and genes.

Authors: Martin Leeb; Diego Pasini; Maria Novatchkova; Markus Jaritz; Kristian Helin; Anton Wutz
Journal: Genes Dev Date: 2010-02-01 Impact factor: 11.361

8. Activated p53 suppresses the histone methyltransferase EZH2 gene.

Authors: Xiaohu Tang; Michael Milyavsky; Igor Shats; Neta Erez; Naomi Goldfinger; Varda Rotter
Journal: Oncogene Date: 2004-07-29 Impact factor: 9.867

9. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression.

Authors: John R Prensner; Matthew K Iyer; O Alejandro Balbin; Saravana M Dhanasekaran; Qi Cao; J Chad Brenner; Bharathi Laxman; Irfan A Asangani; Catherine S Grasso; Hal D Kominsky; Xuhong Cao; Xiaojun Jing; Xiaoju Wang; Javed Siddiqui; John T Wei; Daniel Robinson; Hari K Iyer; Nallasivam Palanisamy; Christopher A Maher; Arul M Chinnaiyan
Journal: Nat Biotechnol Date: 2011-07-31 Impact factor: 54.908

10. ATRA inhibits the proliferation of DU145 prostate cancer cells through reducing the methylation level of HOXB13 gene.

Authors: Zhiwei Liu; Guoling Ren; Chenyan Shangguan; Lijing Guo; Zhixiong Dong; Yueyang Li; Weina Zhang; Li Zhao; Pingfu Hou; Yu Zhang; Xiuli Wang; Jun Lu; Baiqu Huang
Journal: PLoS One Date: 2012-07-13 Impact factor: 3.240

63 in total

1. Properties of Native High-Density Lipoproteins Inspire Synthesis of Actively Targeted In Vivo siRNA Delivery Vehicles.

Authors: Kaylin M McMahon; Michael P Plebanek; C Shad Thaxton
Journal: Adv Funct Mater Date: 2016-09-20 Impact factor: 18.808

2. C10ORF12 modulates PRC2 histone methyltransferase activity and H3K27me3 levels.

Authors: Yi Shi; Hong-Lei Ma; You-Wen Zhuang; Xiao-Xi Wang; Yi Jiang; H Eric Xu
Journal: Acta Pharmacol Sin Date: 2019-06-11 Impact factor: 6.150

Review 3. DNA methylation in development and disease: an overview for prostate researchers.

Authors: Diya B Joseph; Douglas W Strand; Chad M Vezina
Journal: Am J Clin Exp Urol Date: 2018-12-20

4. Epigenetic Suppression of SERPINB1 Promotes Inflammation-Mediated Prostate Cancer Progression.

Authors: Irina Lerman; Xiaoting Ma; Christina Seger; Aerken Maolake; Maria de la Luz Garcia-Hernandez; Javier Rangel-Moreno; Jessica Ackerman; Kent L Nastiuk; Martha Susiarjo; Stephen R Hammes
Journal: Mol Cancer Res Date: 2019-01-04 Impact factor: 5.852

Review 5. Prostate cancer epigenome.

Authors: Swathi Chinaranagari; Pankaj Sharma; Nathan J Bowen; Jaideep Chaudhary
Journal: Methods Mol Biol Date: 2015

6. Interleukin-1β-mediated suppression of microRNA-101 and upregulation of enhancer of zeste homolog 2 is involved in particle-induced lung cancer.

Authors: You-Ming Lei; Yun-Fen Zu; Jiying Wang; Song Bai; Yun-Fei Shi; Rou Shi; Jin Duan; Daolei Cui; Jianlan Chen; Yang Xiang; Jian Dong
Journal: Med Oncol Date: 2014-11-27 Impact factor: 3.064

7. miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src.

Authors: Xu-Bao Shi; Ai-Hong Ma; Lingru Xue; Meimei Li; Hao G Nguyen; Joy C Yang; Clifford G Tepper; Regina Gandour-Edwards; Christopher P Evans; Hsing-Jien Kung; Ralph W deVere White
Journal: Cancer Res Date: 2015-11-16 Impact factor: 12.701

Review 8. Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications.

Authors: Wei Wang; Jiang-Jiang Qin; Sukesh Voruganti; Subhasree Nag; Jianwei Zhou; Ruiwen Zhang
Journal: Med Res Rev Date: 2015-07-30 Impact factor: 12.944

9. Inhibition of EZH2 Enhances the Antitumor Efficacy of Metformin in Prostate Cancer.

Authors: Yifan Kong; Yanquan Zhang; Fengyi Mao; Zhuangzhuang Zhang; Zhiguo Li; Ruixin Wang; Jinghui Liu; Xiaoqi Liu
Journal: Mol Cancer Ther Date: 2020-10-06 Impact factor: 6.261

10. Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate.

Authors: Habiba Elfandy; Joshua Armenia; Filippo Pederzoli; Eli Pullman; Nelma Pertega-Gomes; Nikolaus Schultz; Kartik Viswanathan; Aram Vosoughi; Mirjam Blattner; Konrad H Stopsack; Giorgia Zadra; Kathryn L Penney; Juan Miguel Mosquera; Svitlana Tyekucheva; Lorelei A Mucci; Christopher Barbieri; Massimo Loda
Journal: Mol Cancer Res Date: 2018-10-17 Impact factor: 5.852